AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims

1. **(Currently Amended)** A bispecific molecule comprising an anti-CR1 antibody linked to a non-neutralizing antibody that specifically binds to *S. aureus* protein A ~~a bacterial antigen or toxin~~.

2.-64. **(Cancelled)**

65. **(Previously Presented)** The bispecific molecule of claim 1, wherein the anti-CR1 antibody is cross-linked to the non-neutralizing antibody.

66. **(Previously Presented)** The bispecific molecule of claim 1, wherein at least one of the anti-CR1 antibody and the non-neutralizing antibody are monoclonal antibodies.

67. **(Currently Amended)** The bispecific molecule of claim 1, wherein ~~one or more of the antibodies is~~ at least one of the anti-CR1 antibody and the non-neutralizing antibody are modified to reduce its immunogenicity.

68. **(Currently Amended)** The bispecific molecule of claim 65, wherein ~~one or more of the antibodies is~~ at least one of the anti-CR1 antibody and the non-neutralizing antibody are deimmunized.

69. **(Currently Amended)** The bispecific molecule of claim 1, wherein ~~one or more of the antibodies is~~ at least one of the anti-CR1 antibody and the non-neutralizing antibody are an antigen binding fragment of an antibody.

70. **(Previously Presented)** The bispecific molecule of claim 69, wherein the antigen binding fragment is selected from the group consisting of a Fab, Fab', $(Fab')_2$, Fv, scFv, or scab fragment of an antibody.

71. **(Currently Amended)** The bispecific molecule of claim 1, wherein ~~one or more of the antibodies is~~ at least one of the anti-CR1 antibody and the non-neutralizing antibody are a full length antibody.

72. **(Previously Presented)** The bispecific molecule of claim 63, wherein the anti-CR1 antibody and the non-neutralizing antibody are crosslinked using a crosslinking agent.

73. **(Previously Presented)** The bispecific molecule of claim 67, wherein the crosslinking agent is polyethylene glycol (PEG).

74. **(Previously Presented)** The bispecific molecule of claim 1, wherein the anti-CR1 antibody is 7G9.

75. **(Previously Presented)** The bispecific molecule of claim 1, wherein the anti-CR1 antibody is 19E9.

76. **(Currently Amended)** A bispecific molecule comprising an anti-CR1 antibody linked to an antibody that is selected from the group consisting of: 3F3, 2F9, 3F10, 3D2, 16E11, 2C11, 6C3, and a non-neutralizing ~~an~~ antibody that recognizes *S. aureus* Protein A.